[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methamphetamine-abuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methamphetamine-abuse":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,68,102,131,159,185,208],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100534051",false,"NCT06233799","Trial of Naltrexone\u002FBupropion for the Treatment of Methamphetamine Use Disorder","Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection\u002FBupropion XL Tablets in the Treatment of Methamphetamine Use Disorder","Inclusion Criteria:\n\n1. Is 18 to 65 years of age;\n2. Meets DSM-5 criteria for moderate or severe MUD (4 or more criteria);\n3. Is interested in reducing or stopping MA use;\n4. Is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study;\n5. Self-reports MA use on 18 or more days in the 30-day period prior to consent using the Timeline Followback (TLFB);\n6. Provides at least 2 urine samples positive for MA out of up to 3 tests, which will occur at least 2 days apart within a 10-day period;\n7. If assigned as female at birth and\u002For currently has a uterus, is not pregnant, agrees to use acceptable birth control methods, and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided;\n8. Is not physically dependent on opioids and meets subjective and objective measures of being opioid-free prior to naltrexone injection per study medical clinician's determination, including, if clinically required, a negative naloxone challenge;\n9. Is willing to comply with all study procedures and medication instructions;\n10. Agrees to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing.\n\nExclusion Criteria:\n\n1. Has an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe;\n2. Has suicidal or homicidal ideation that requires immediate attention;\n3. Has a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician;\n4. Has evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study;\n5. Has Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160\u002F100 in 2 out of 3 readings during screening);\n6. Has any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value \\> 5 times the upper limit of normal per laboratory criteria;\n7. Has a platelet count \\\u003C100 x 10exp3\u002Fmicroliter;\n8. Has a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures;\n9. Has a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactideco-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents;\n10. Has been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent;\n11. Has taken an investigational drug in another study within 30 days of study consent;\n12. Has been prescribed and taken naltrexone or bupropion within 30 days of study consent;\n13. Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder (SUD) treatment services;\n14. Is receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications;\n15. Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician;\n16. Requires treatment with opioid-containing medications (e.g., opioid analgesics) during the study period;\n17. Has a surgery planned or scheduled during the study period;\n18. Is currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities;\n19. If assigned as female at birth and\u002For currently has a uterus, is currently pregnant, breastfeeding, or planning on conception.","ALL","18 Years","65 Years",{"count":19,"type":20},360,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX\u002FBUP-XL) compared to matched injectable and oral placebo (iPLB\u002FoPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.",[26,27],"Methamphetamine-dependence","Methamphetamine Abuse","RECRUITING","2026-06-01",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":32},"2024-07-01",{"date":36,"type":20},"2027-04-30",{"name":38,"class":39},"National Institute on Drug Abuse (NIDA)","NIH",11,{"id":42,"slug":43,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100554258","phase-2-ketamine-for-methamphetamine-use-disorder-100554258","NCT06496750","Ketamine for Methamphetamine Use Disorder","NIDA CTN-0132 Randomized, Double-Blind, Active Placebo-Controlled Trial of Ketamine for Methamphetamine Use Disorder (KMD)","KMD","Inclusion criteria\n\nStudy participants must:\n\n1. Be 18 to 65 years old\n2. Be able to sufficiently understand, speak, and read English\n3. Be interested in reducing or stopping methamphetamine use\n4. Meet criteria for methamphetamine use disorder\n5. Use acceptable methods of contraception during participation in the study\n\nExclusion criteria\n\nStudy participants must not:\n\n1. Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent\n2. Be currently in jail, prison, or inpatient overnight facility as required by court of law\n3. Have upcoming surgery planned or scheduled\n4. Be currently pregnant, breastfeeding, or planning on conception, if biologically female\n\nAdditional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.",{"count":50,"type":20},120,[52],"PHASE2","This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.\n\nThe study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).",[55,56,27],"Substance Use Disorders","Substance Use","2026-03-30",{"date":59,"type":32},"2026-04-01",{"date":61,"type":32},"2024-09-11",{"date":63,"type":20},"2026-10-15",{"name":65,"class":66},"University of Texas Southwestern Medical Center","OTHER",5,{"id":69,"slug":70,"hasResults":10,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100576691","phase-2-feasibility-of-long-term-high-dose-stimulant-for-methamphetamine-use-disorder-100576691","NCT06788587","Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Between 18 and 55 years of age at enrollment in the parent ASCME trial;\n2. Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria;\n3. Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1;\n4. Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use;\n5. Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD;\n6. If female:\n\n   * Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n   * Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n7. Willing to be randomized to one of 2 study arms and followed for the duration of the trial;\n8. Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002);\n9. Able to provide informed consent;\n10. Willing to comply with study procedures;\n11. Able to communicate in English or French\n\nExclusion Criteria:\n\n1. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent;\n2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study;\n3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for \\\u003C12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C4 weeks;\n4. Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study;\n5. History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines;\n6. Pregnant, nursing, or planning to become pregnant during the study period;\n7. Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study;\n8. Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial;\n9. Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening;\n10. Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician;\n11. ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening;\n12. Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study;\n13. Any compliance issues related to the study product and\u002For study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study.","55 Years",{"count":77,"type":20},80,[52],"Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.\n\nThe goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.\n\nParticipants will be placed randomly into one of two groups:\n\n1. TAU and high-dose LDX-01\n2. TAU and placebo",[27,26,81,82,83],"Addiction","Substance Abuse","Methamphetamine Use Disorder",[85,86,87,88,89,90,91],"Substance use disorder","Amphetamines","Methamphetamine","Lisdexamfetamine","Treatment","Agonist therapy","Feasibility","2026-02-19",{"date":94,"type":32},"2026-02-23",{"date":96,"type":32},"2025-07-18",{"date":98,"type":20},"2027-12",{"name":100,"class":66},"Centre hospitalier de l'Université de Montréal (CHUM)",1,{"id":103,"slug":104,"hasResults":10,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":10,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100499531","methamphetamine-prep-and-intersectional-stigma-study-100499531","NCT05784467","Methamphetamine, PrEP, and Intersectional Stigma Study","Addressing Intersectional Stigma Through Coping, Resistance, and Resilience to Improve Methamphetamine Use and Factors Influencing PrEP Uptake Among Latino MSM: a Step Towards Ending HIV by 2030","eMPrISe","Inclusion Criteria:\n\n* 18+ years of age\n* cisgender male\n* self-identify as Latino or Hispanic\n* fluent in English or Spanish\n* any sexual activity with men in the past 12 months\n* HIV-negative\n* moderate methamphetamine use risk (as determined by the the ASSIST assessment)\n* experience of intersectional stigma within their social network in the past 12 months\n* willing to provide written informed consent\n\nExclusion Criteria:\n\n* N\u002FA","MALE",{"count":112,"type":20},20,[114],"NA","The goal of this clinical trail is to test the developed eMPrISe study in HIV-negative, adult, Latino men who have sex with men (MSM) who use non-injection substances. The main questions it aims to answer are:\n\n* Can participation in the developed eMPrISe study reduce methamphetamine ('meth') use risk?\n* Can participation in the developed eMPrISe study improve preexposure prophylaxis (PrEP) cascade progression? Participants will participate in 12 weekly modules that: (1) build critical thinking skills, (2) identify and discuss the link between oppression and harmful behaviors, (3) take action, (4) voice and validate feelings and experiences, and (5) share knowledge and resources.",[27,117,118],"Hiv","Social Stigma",[87,120,121],"Preexposure prophylaxis","Intersectional Stigma","NOT_YET_RECRUITING","2026-02-17",{"date":92,"type":32},{"date":126,"type":20},"2026-04-15",{"date":128,"type":20},"2027-08-31",{"name":130,"class":66},"Arizona State University",{"id":132,"slug":133,"hasResults":10,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":146,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100433670","encouraging-abstinence-behavior-in-a-drug-epidemic-optimizing-dynamic-incentives-100433670","NCT04927143","Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives","Inclusion Criteria:\n\n* Age at least 18 years old;\n* Meet DSM-5 OUD, CoUD, or MUD criteria as evidenced by an OUD CPT code F11\\* (opioid related disorders), a CoUD CPT code F14\\* (cocaine related disorders), a MUD CPT code F15.1\u002FF15.2 or other clinical notes indicating illicit opioid\u002Fcocaine\u002Fmethamphetamine use for treatment\n* Have access to a smartphone (iOS or Android) with data plan and willing to download DynamiCare app;\n* Have an email and can access it from their smartphone;\n* Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment;\n* Are likely to be helped by contingency management because at least ONE of the following conditions is true:\n\n  1. Were first enrolled in residential, PHP, or IOP substance use treatment no longer than 2 treatment weeks (14 days\u002Fencounters of treatment) prior to providing informed consent.\n  2. Used non-medical opioids, cocaine, and\u002For methamphetamine within the last 21 days.\n* Understands English.\n\nExclusion Criteria:\n\n* Have evidence of active (non-substance related) psychosis that might impair participation as determined by the PI.\n* Has significant cognitive impairment that might confound participation as determined by the PI or are so significantly cognitively impaired that they have a legal guardian.",{"count":138,"type":20},600,[114],"Combatting the rise of the opioid epidemic is a central challenge of U.S. health care policy. A promising approach for improving welfare and decreasing medical costs of people with substance abuse disorders is offering incentive payments for healthy behaviors. This approach, broadly known as \"contingency management\" in the medical literature, has repeatedly shown to be effective in treating substance abuse. However, the use of incentives by treatment facilities remains extremely low. Furthermore, it is not well understood how to design optimal incentives to treat opioid abuse. This project will conduct a randomized evaluation of two types of dynamically adjusting incentive schedules for people with opioid use disorders or cocaine use disorders: \"escalating\" schedules where incentive amounts increase with success to increase incentive power, and \"de-escalating\" schedules where incentive amounts decrease with success to improve incentive targeting. Both schemes are implemented with a novel \"turnkey\" mobile application, making them uniquely low-cost, low-hassle, and scalable. Effects will be measured on abstinence outcomes, including longest duration of abstinence and the percentage of negative drug tests. In combination with survey data, variation from the experiment will shed light on the barriers to abstinence more broadly and inform the understanding of optimal incentive design.",[142,143,144,145,56,27,26],"Opioid-use Disorder","Cocaine Use Disorder","Opioid Use","Cocaine Use",[147,148],"contingency management","app-based treatment","2026-02-09",{"date":151,"type":32},"2026-02-12",{"date":153,"type":32},"2021-09-15",{"date":155,"type":20},"2026-09",{"name":157,"class":66},"Wake Forest University Health Sciences",2,{"id":160,"slug":161,"hasResults":10,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":166,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100504925","phase-2-clinical-trial-of-high-dose-lisdexamfetamine-and-contingency-management-in-ma-users-100504925","NCT05854667","Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","Addition of High Dose Stimulant and Engagement-focused Contingency Management (CM), Alone and in Combination, to Treatment as Usual (TAU) for the Management of Methamphetamine (MA) Use Disorder (ASCME): a Canadian Multi-centre, RCT","Inclusion Criteria:\n\n* Participant must meet all the following criteria:\n\n  1. Between 18 and 55 years of age;\n  2. Diagnosed with a moderate to severe methamphetamine (MA) use disorder as defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria;\n  3. Active MA use at screening measured via self-reported MA use ≥14 days in the past 28 days AND verified by urine drug metabolite testing;\n  4. Interested in reducing\u002Fstopping MA use;\n  5. If female:\n\n     1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n     2. Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n  6. Willing to be randomized to one of the 4 study arms and followed for the duration of the trial;\n  7. Able to provide informed consent;\n  8. Willing to comply with study procedures;\n  9. Able to communicate in English or French.\n\nExclusion Criteria:\n\n* 1\\. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; current hyperthyroidism confirmed via blood test; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, OR unstable medical condition that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent; 2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study; 3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Therapy (OAT) for \\\u003C 12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C 4 weeks; 4. Current or history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study; 5. History of a severe adverse event, hypersensitivity or known allergic reaction to LDX or other amphetamine drugs OR hypersensitivity to the sympathomimetic amines; 6. Pregnant, nursing, or planning to become pregnant during the study period; 7. Planned extended absence during study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study; 8. Use of an investigational drug for stimulant use disorder during the 30 days prior to screening, confirmed via self-report OR pharmacy records; 9. Currently receiving contingency management for the treatment of stimulant use disorder in the 4 weeks prior to screening, confirmed via self-report OR site records; 10. Use of prescribed amphetamine-type medication OR medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion) in the 4 weeks prior to screening; 11. Current or anticipated need for treatment with any medication that may interact with LDX (e.g., proton pump inhibitors, monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days AND that would preclude study participant at the discretion of the study physician",true,{"count":168,"type":20},440,[52],"The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic.\n\nThe main questions the trial aims to answer are:\n\nIs a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine?\n\nParticipants will be placed randomly into one of four groups:\n\n1. Usual treatment and placebo\n2. Usual treatment, placebo and contingency management\n3. Usual treatment and high dose stimulant\n4. Usual treatment, high dose stimulant and contingency management\n\nParticipation includes the following:\n\n1. Participants will receive medication or placebo weekly for 15 weeks.\n2. Participants will attend the clinic for weekly treatment\n3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.",[27,26,172,81],"Addiction, Substance",[174,175],"Contingency Management","Treatment as Usual","2026-02-03",{"date":178,"type":32},"2026-02-05",{"date":180,"type":32},"2023-12-05",{"date":182,"type":20},"2028-04",{"name":100,"class":66},4,{"id":186,"slug":187,"hasResults":10,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":101},"100571533","phase-2-a-single-dose-study-to-evaluate-safety-and-efficacy-of-cs-1103-in-participants-receiving-a-single-dose-of-methamphetamine-100571533","NCT06721494","A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine","A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine","Major Inclusion Criteria:\n\n1. Healthy participants aged 18 to 55 years, inclusive;\n2. Meets DSM-5 criteria for methamphetamine use disorder;\n3. Not seeking treatment for methamphetamine use disorder;\n4. Primary route of methamphetamine self-administration must be intravenous or smoking;\n5. Able to abstain from methamphetamine without experiencing severe withdrawal;\n6. A body mass index between 18 to 30 kg\u002Fm2, inclusive and a minimum body weight of 50 kg;\n7. Females must not be lactating and must have a negative pregnancy test during screening and admission.\n\nMajor Exclusion Criteria:\n\n1. Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2;\n2. History of cardiovascular disease;\n3. Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;\n4. History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.",{"count":193,"type":20},40,[52],"The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).",[197,198,27],"Methamphetamine Intoxication","Methamphetamine Disorders","2026-01-09",{"date":201,"type":32},"2026-01-12",{"date":178,"type":20},{"date":204,"type":20},"2026-09-11",{"name":206,"class":207},"Clear Scientific, Inc.","INDUSTRY",{"id":209,"slug":210,"hasResults":10,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":10,"sex":214,"minAge":16,"maxAge":17,"enrollmentInfo":215,"targetDuration":4,"studyType":217,"phases":4,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100616757","maternal-outcomes-with-methamphetamine-use-and-cardiac-assessment-for-rural-dissemination-mom-card-100616757","NCT07309757","Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)","Inclusion Criteria:\n\n* 18 years or older \\> 20 weeks gestation admitted to the hospital\n* Active patient-defined regular methamphetamine use for at least 1 year and any use within the last month\n* Able to understand and provide informed consent\n* Able to understand English\n\nExclusion Criteria:\n\nThese criteria will exclude women whose medications, personal traits, obstetric conditions, or diseases could confound cardiovascular risk.\n\n* Prescribed stimulants\n* Echocardiogram or EKG previously performed during current pregnancy\n* Previous diagnosis of congestive heart dysfunction\n* Previous diagnosis of pulmonary hypertension\n* Previous myocardial infarction\n* Previous diagnosis of endocarditis\n* Prior cardiac intervention (repair of cardiac congenital lesion, valve replacement or repairs, percutaneous\u002Foperative treatment of arrhythmias)\n* High-risk aortopathy (Marfan syndrome, bicuspid aortopathy, prior aortic dissection)","FEMALE",{"count":216,"type":20},35,"OBSERVATIONAL","The purpose of this study is to develop a pilot screening protocol, comparing cardiac point-of-care ultrasound (POCUS), electrocardiogram (EKG), serum biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTn)) with formal transthoracic echocardiogram (TTE) in pregnant women with methamphetamine use.",[27],[221,222,223],"Methamphetamine use","Pregnancy","Cardiomyopathy","2025-12-29",{"date":226,"type":32},"2026-01-02",{"date":228,"type":20},"2026-02-01",{"date":230,"type":20},"2027-12-31",{"name":232,"class":66},"Oregon Health and Science University"]